Custom gene synthesis is needed to complete studies on how gene regulation of the immune cells impacts human health and diseases.
Ended Awarded Last action
- Contract number
- 75N92B20F00017
- Awardee
-
Genscript USA Inc. UEI KVLBRRAQ6UX1
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,557
Award facts
- Contract value 100% obligated
- $12,557.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621991 Blood and Organ Banks
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Piscataway, NJ 08854, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5,456 | |
| Original award | $18,014 |
About this award
The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a blanket purchase agreement (BPA) call to Genscript USA Inc. on July 9, 2020, for custom gene synthesis services to support immunological research. The contract, valued at $12,557.49 with firm fixed pricing, was executed without a set-aside designation and completed on June 30, 2021. Genscript USA Inc., a biotechnology company headquartered in Piscataway, New Jersey, provided the gene synthesis work performed at its Piscataway location to enable studies examining how gene regulation of immune cells impacts human health and disease outcomes.
This BPA call represents part of Genscript's broader engagement as a critical federal research contractor specializing in advanced molecular biology services. The company has established significant relationships across multiple health-related agencies, including the National Institutes of Health, Centers for Disease Control and Prevention, and the Food and Drug Administration, delivering services ranging from gene synthesis to antibody development. Genscript's expertise in custom biological research materials directly supports the National Institute of Arthritis and Musculoskeletal and Skin Diseases' mission to advance understanding of immune system function and its role in various disease states.
Quick answers
Who was awarded contract 75N92B20F00017?
75N92B20F00017 was awarded to Genscript USA Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on July 9, 2020.
How much is contract 75N92B20F00017 worth?
The government has obligated $12,557 on 75N92B20F00017.
Is contract 75N92B20F00017 an order under another contract?
Yes. 75N92B20F00017 is a BPA call under HHSN263201400039B, a blanket purchase agreement.
Was contract 75N92B20F00017 competed?
The extent of competition for 75N92B20F00017 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award